Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
Sponsor: Sunnybrook Health Sciences Centre
Summary
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.
Official title: Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2016-07-16
Completion Date
2026-12-31
Last Updated
2024-04-12
Healthy Volunteers
No
Interventions
Stereotactic Body Radiation Therapy (SABR)
SABR to oligoprogressive metastases while continuing abiraterone therapy
Locations (1)
Odette Cancer Centre
Toronto, Ontario, Canada